Foster Victor Wealth Advisors LLC Purchases 18,162 Shares of Pfizer Inc. (NYSE:PFE)

Foster Victor Wealth Advisors LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 4.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 451,419 shares of the biopharmaceutical company’s stock after purchasing an additional 18,162 shares during the period. Foster Victor Wealth Advisors LLC’s holdings in Pfizer were worth $13,628,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC bought a new position in shares of Pfizer in the second quarter worth about $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer in the second quarter worth about $29,000. Quarry LP bought a new position in shares of Pfizer in the second quarter worth about $31,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the fourth quarter worth about $32,000. Finally, Trivant Custom Portfolio Group LLC raised its stake in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 1.3 %

Shares of NYSE PFE opened at $29.46 on Wednesday. The stock has a market cap of $166.94 billion, a P/E ratio of -491.00, a P/E/G ratio of 1.30 and a beta of 0.67. The firm has a 50 day moving average price of $29.02 and a 200 day moving average price of $28.41. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $33.92.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the previous year, the firm posted $0.67 earnings per share. The business’s revenue was up 2.1% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.70%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is currently -2,800.00%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Thursday, October 3rd. Finally, UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.